Universal Beteiligungs und Servicegesellschaft mbH Sells 60,082 Shares of IDEXX Laboratories, Inc. $IDXX

Universal Beteiligungs und Servicegesellschaft mbH decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 113,245 shares of the company’s stock after selling 60,082 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of IDEXX Laboratories worth $72,351,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Opal Wealth Advisors LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $30,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories during the 3rd quarter worth about $31,000. Armstrong Advisory Group Inc. lifted its holdings in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth about $35,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on IDXX shares. Jefferies Financial Group restated a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, January 12th. Barclays assumed coverage on IDEXX Laboratories in a research report on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective on the stock. UBS Group boosted their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday, November 3rd. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $686.02 on Wednesday. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $54.78 billion, a P/E ratio of 54.40, a PEG ratio of 3.83 and a beta of 1.67. The stock has a 50-day moving average price of $706.30 and a 200-day moving average price of $653.13. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.